Ultimovacs Financial Statements From 2010 to 2024
| ULTI Stock | NOK 1.98 0.05 2.46% |
Check Ultimovacs ASA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ultimovacs ASA's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ultimovacs financial statements analysis is a perfect complement when working with Ultimovacs ASA Valuation or Volatility modules.
Ultimovacs |
Ultimovacs ASA Company Return On Equity Analysis
Ultimovacs ASA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Ultimovacs ASA Return On Equity | -0.33 |
Most of Ultimovacs ASA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ultimovacs ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Ultimovacs ASA has a Return On Equity of -0.3318. This is 98.62% lower than that of the Healthcare sector and 99.09% lower than that of the Biotechnology industry. The return on equity for all Norway stocks is 7.03% higher than that of the company.
Ultimovacs ASA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ultimovacs ASA's current stock value. Our valuation model uses many indicators to compare Ultimovacs ASA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ultimovacs ASA competition to find correlations between indicators driving Ultimovacs ASA's intrinsic value. More Info.Ultimovacs ASA is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ultimovacs ASA's earnings, one of the primary drivers of an investment's value.About Ultimovacs ASA Financial Statements
Ultimovacs ASA investors utilize fundamental indicators, such as revenue or net income, to predict how Ultimovacs Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. The company was incorporated in 2011 and is headquartered in Oslo, Norway. ULTIMOVACS ASA is traded on Oslo Stock Exchange in Norway.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.